Suzhou Leadsynbio Technology Co.,Ltd. Leadsynbio logo

1f1489b6fabc4e90926f77e54ab84437_4

News | Leadsynbio achieves dual compliance with Self-GRAS and NDI

font: BigMiddleSmall

Date: Nov 16,2026
[Article guide] Recently, Leadsynbio’s microbially fermentation-based β-nicotinamide mononucleotide (NMN) reached another core U.S. market compliance milestone, officially receiving a New Dietary Ingredient (NDI) No Objection Letter from the U.S. FDA, with NDIN No. 1497.

Recently, Leadsynbio’s microbially fermentation-based β-nicotinamide mononucleotide (NMN) achieved another core U.S. market compliance milestone, receiving a New Dietary Ingredient (NDI) No Objection Letter from the U.S. FDA, with NDIN No. 1497. Following successful Self-GRAS safety assessment, Leadsynbio’s fermented NMN now holds both Self-GRAS and NDI core compliance qualifications, making us one of the earlier raw material suppliers in China to achieve industrial-scale NMN production via microbial fermentation and complete a dual compliance layout under the U.S. regulatory system. Within the U.S. DSHEA dietary supplement regulatory framework, NDI is a pre-launch safety notification review mechanism for dietary supplement ingredients. The FDA’s issuance of the No Objection Letter indicates that, within the use scenarios and dosage levels stated in the notification, Leadsynbio’s fermentation-based NMN has sufficient safety support. The two compliance pathways complement each other, enabling the ingredient to serve both mainstream U.S. application tracks: conventional foods and dietary supplements, and providing global downstream customers with safe, stable, and traceable compliant raw material solutions.

resource/images/0cd07240fa594c8386c2fc4a1a2e2aee_22.jpg

Leadsynbio’s NMN is produced via a microbial fermentation route. Supported by our proprietary strain construction, fermentation process scale-up, purification, and full-chain quality control platforms, the process is low-carbon, environmentally friendly, and highly sustainable, aligning with the global health industry’s direction toward green biomanufacturing.

Building on our mature fermentation industrialization platform, we have established hundred-ton-scale fermentation-based NMN production capacity, supported by a cGMP-compliant manufacturing system. With the NDI qualification now in place, Leadsynbio will integrate Self-GRAS safety assessment conclusions, NDI No Objection Letter, cGMP production system, and large-scale supply capability into a differentiated competitive advantage. We will continue to iterate our fermentation process, steadily advance capacity planning, strictly control batch-to-batch consistency, and ensure long-term stable delivery. Serving the global conventional food and dietary supplement markets, Leadsynbio will continue to focus on green biomanufacturing, and strive to become a long-term trusted biomanufacturing raw material partner for global customers.

Suzhou Leadsynbio Technology Co.,Ltd.©Copyright